Seres Therapeutics, Inc.
Quick facts
Phase 3 pipeline
- SER-109 · Infectious Disease / Gastroenterology
SER-109 is a spore-based microbiome therapeutic that restores healthy gut bacterial composition to prevent recurrent Clostridioides difficile infection.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Seres Therapeutics, Inc.
What is Seres Therapeutics, Inc.'s pipeline?
Seres Therapeutics, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 3 in Phase 1. Late-stage candidates include SER-109.
Related
- Sector hub: All tracked pharma companies